SNN

Business Context and Reporting Period

Company: Smith & Nephew plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: A global medical devices company operating in four primary segments: Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy, and Advanced Wound Management. The company is incorporated in England and Wales, with shares listed on the London Stock Exchange and American Depositary Shares (ADSs) on the New York Stock Exchange.

Key Financial Metrics

Note: 2006 Attributable Profit includes a $351 million one-time gain from the disposal of the BSN Medical joint venture.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 21% to $3.37 billion. Underlying growth was 10%, with acquisitions contributing 7% and favorable currency translation adding 4%.
• Acquisitions: The company acquired Plus Orthopedics Holding AG ($889 million) and BlueSky Medical Group Inc. ($15 million initial payment) in 2007, significantly expanding its orthopaedic and wound management portfolios.
• Profitability Decline: GAAP Operating Profit decreased 8% to $493 million, and Attributable Profit dropped 58% to $316 million. This decline is primarily due to the absence of the $351 million BSN Medical disposal gain recorded in 2006, offset by higher acquisition-related costs ($111 million), restructuring expenses ($42 million), and a legal settlement ($30 million).
• Adjusted Performance: Adjusted Attributable Profit increased 13% to $480 million, reflecting underlying operational growth.
• Liquidity Shift: The company moved from a net cash position of $210 million in 2006 to net debt of $1.31 billion in 2007, driven by acquisition financing and a $640 million share buyback program.

Guidance, Outlook, and Risks

• Outlook: Management expects 2008 revenue growth in Reconstruction to exceed market growth (estimated at 9% in 2007). Trauma and Clinical Therapies growth is expected to be close to the market rate (10%). Endoscopy growth is expected to be slightly below market rates due to a slower growth resection segment. Advanced Wound Management growth is expected to slightly exceed market rates, with material growth from the BlueSky product launch.
• Earnings Improvement Programme (EIP): The company targets an increase in trading profit margins of at least 1% per annum through 2010. It also targets $40 million in annual cost savings from the Plus acquisition by the third full year.
• Share Buyback: The company expects to complete its $1.5 billion share buyback program over a total of three years (extended from the original two-year timeline).
• Key Risks:
  • Product Liability: Ongoing litigation regarding macrotextured knee components. A provision of $41 million remains for future claims, with $113 million due from insurers who have declined coverage.
  • Regulatory: Investigations by the US Department of Justice (Antitrust) and the SEC (Foreign Corrupt Practices Act) regarding marketing practices in Europe and the US. A $29 million civil restitution payment was made in 2007 to settle a US Department of Justice investigation.
  • Market Competition: Highly competitive markets with significant consolidation among competitors (e.g., Zimmer, Stryker, DePuy).

Investor Verification Checklist

• Macrotextured Knee Liability: Verify the adequacy of the $41 million provision against the $113 million receivable from insurers who have denied coverage. Monitor the outcome of the breach of contract suit against insurers.
• Regulatory Investigations: Monitor the status of the SEC investigation into marketing practices in Germany, Poland, and Greece, and the DOJ Antitrust investigation.
• Acquisition Integration: Assess the integration progress of Plus Orthopedics and BlueSky, specifically regarding the realization of projected synergies and cost savings.
• Debt Levels: Review the impact of the increased net debt ($1.31 billion) on interest expenses and financial covenants, particularly the net debt to EBITDA ratio.
• Non-GAAP Reconciliations: Review the reconciliation of GAAP Operating Profit to Trading Profit and Attributable Profit to Adjusted Attributable Profit to understand the magnitude of one-time charges (acquisition costs, restructuring, legal settlements).